A call for free services is running by EURIPRED. EURIPRED facilitates and supports translational research for poverty related diseases, such as HIV, TB, malaria and hepatitis.
The free services are: • Access to biological materials and reference reagents/standards facilitated by the National Institute of Biological Standards and Control (NIBSC), UK; • Access to microarray facility for screening & evaluation facilitated by JPT Peptide Technologies, Germany.
Applications will be assessed within about three weeks on receipt.
A new paper related to the MVVC project has recently been published in the PLoS One journal.
EVI has expanded its portfolio in a new disease of poverty through the recently initiated ZIKAVAX project.
The following influenza reagents are now available on the NIBSC website:
Influenza Virus Infectious X-283A 42420 ExE1
Influenza Virus Infectious X-285A 42440 ExE1
Influenza Virus Infectious X-285 42430 ExE1
GloPID-R Zika Virus Research Workshop was held in Sao Paulo, Brazil on November 30 – December 2, 2016. The workshop’s aim was to identify and establish collaboration and synergies between the research and capacity development projects in support of the Zika virus response in Latin America and the Caribbean funded by GloPID-R members worldwide. EVI was represented by Nicola Viebig.
The deadline for oral abstract submissions is Friday 2nd December 2016.
Two new influenza reagents are now available. Influenza anti-A/Michigan/45/2015-like HA serum and Influenza Antigen A/Singapore/GP1908/2015 serum are now available through the NIBSC website.
SAP has released a short video featuring the European Vaccine Initiative. See how the use of the SAP system is helping EVI to simplify the management process. The video is available on the EVI YouTube channel.
The Influenza anti-A Switzerland/9715293/2013-Like HA serum (sheep 618, 619, 628, 634, 635 & 636) is now available on the NIBSC website.
EVI extends a warm welcome to Siaka Débé. Mr Débé joins EVI with a fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO). He began his one-year Clinical Research and Development fellowship on 14 November.